ライフサイエンスコーパス: imipenem

1 her resistance or intermediate resistance to imipenem).

2 hat were not susceptible to meropenem and/or imipenem.

3 -1 and GES-5 beta-lactamases in complex with imipenem.

4 ient for manifestation of resistance against imipenem.

5 ent reaction intermediate with the substrate imipenem.

6 of drugs like ceftazidime, penicillins, and imipenem.

7 onferring resistance to all beta-lactams but imipenem.

8 to 5-21 days imipenem/relebactam or colistin+imipenem.

9 esting susceptibility of enterococci against imipenem.

10 es, as did 130 of the 162 (80%) treated with imipenem.

11 received imipenem/relebactam and 16 colistin+imipenem.

12 ccurately predicted the in vitro activity of imipenem.

13 species against cefoxitin, doxycycline, and imipenem.

14 interpretive category was most variable for imipenem.

15 d the hydrolytic activity for penicillin and imipenem.

16 ed hydrolytic activity for cephaloridine and imipenem.

17 t were resistant to most beta-lactams except imipenem.

18 actual two- to fourfold increases in MICs of imipenem.

19 e classification of isolates as resistant to imipenem.

20 only 40% of the strains were susceptible to imipenem.

21 erate intrinsic resistance to ampicillin and imipenem.

22 the addition of vancomycin to ampicillin and imipenem.

23 nation with the front line M. abscessus drug imipenem.

24 was 69%-73% for ceftazidime and 41%-50% for imipenem.

25 entified drugs that restored the activity of imipenem.

26 atment with fosfomycin (2 g/6 hours IV) plus imipenem (1 g/6 hours IV) was started and monitored.

27 ensive care units: Doripenem, 0.5%, 8%, 78%; imipenem, 1, 16, 75%; and meropenem, 1, 16, 82%.

28 rcent susceptibility): Doripenem, 1, 8, 69%; imipenem, 2, 16, 67%; and meropenem, 1, 32, 70%; and by

29 cept for Vitek testing (major error rate for imipenem, 20%).

30 (n = 21 imipenem/relebactam, n = 10 colistin+imipenem), 29% had Acute Physiology and Chronic Health E

31 The combinations imipenem/3 and imipenem/4 restored almost completely the

32 The combinations imipenem/3 and imipenem/4 restored almost completely the antibiotic eff

33 eratitis isolates was least for colistin and imipenem (56.52% each).

34 ; meropenem, 72.7%, 1 mug/ml, and 16 mug/ml; imipenem, 67.1%, 2 mug/ml, and 16 mug/ml.

35 00 versus 13%), vancomycin (100 versus 57%), imipenem (94 versus 2%), and high levels of gentamicin (

36 Monitoring the turnover of imipenem (a carbapenem) by GES-1 (Gly-170) revealed the

37 coli growth on increasing concentrations of imipenem, a carbapenem antibiotic.

38 tified; among these, compound 40 potentiates imipenem activity against an NDM-1-producing E. coli cli

39 a-lactamase inhibitor relebactam can restore imipenem activity against imipenem-nonsusceptible gram-n

40 Finally, superimposition of the imipenem-acylated complex with PBP 5 in complex with a b

41 minimum inhibitory concentrations (MICs) of imipenem against clinical isolates of Eschericia coli an

42 curate predictor of the in vitro activity of imipenem against E. faecalis.

43 Treatment with either ampicillin or imipenem alone or in combination with vancomycin resulte

44 Antimicrobial drug (imipenem) alone rescued 9.7% of the animals from death,

45 obial resistance against aminoglycosides and imipenem also was detected.

46 ment by interpretive category was lowest for imipenem and amikacin.

47 n, categorical agreement (CA) for penicillin-imipenem and ampicillin-imipenem tested with E. faecalis

48 Imipenem and ceftazidime have different specificities fo

49 Imipenem and ciprofloxacin significantly reduced the num

50 Survival was significantly improved by imipenem and ciprofloxacin.

51 a prolonged (5-month) course of intravenous imipenem and gentamicin.

52 completely with cefoxitin and partially with imipenem and is absent with cloxacillin, is consistent w

53 Moreover, compound 23 was superior to imipenem and meropenem against highly pathogenic carbape

54 s for Disease Control and Prevention against imipenem and meropenem by agar dilution, disk diffusion,

55 Imipenem and meropenem induced faster killing of E. coli

56 escence on the enzyme, and its reaction with imipenem and meropenem revealed biphasic fluorescence ti

57 For Enterobacteriaceae, the imipenem and meropenem test methods produced low numbers

58 amikacin, tigecycline, and the carbapenems (imipenem and meropenem); 90.8% of Acinetobacter baumanni

59 errors when P. aeruginosa was tested against imipenem and meropenem, except for Vitek testing (major

60 ermeability of two zwitterionic carbapenems, imipenem and meropenem, measured using liposome permeati

61 the differences in the binding properties of imipenem and meropenem, two potent antibiotics of the ca

62 pproximately 1% between penicillins and both imipenem and meropenem, whereas a single study found a c

63 ross-reactivity between penicillins and both imipenem and meropenem, while a single study found a 5.5

64 phalothin analogue and (ii) the carbapenems, imipenem and meropenem.

65 surable activity with carbapenems, including imipenem and meropenem.

66 were conducted on ImiS and its reaction with imipenem and meropenem.

67 ntain a bulky 6(7)alpha substituent, such as imipenem and moxalactam, actually inhibit serine beta-la

68 44 and 1.10 kcal/mol of strain introduced by imipenem and moxalactam, respectively, relative to the w

69 me's thermodynamic stability in complex with imipenem and moxalactam.

70 Using FDA susceptibility breakpoints for imipenem and NCCLS breakpoints for penicillin and ampici

71 erred levels of resistance to the carbapenem imipenem and other beta-lactams.

72 her cure rate could be achieved by combining imipenem and two rechallenges with the Ag pool (p < 0.00

73 Meropenem is closely related to imipenem and was recently approved for use in children.

74 were observed with Proteus mirabilis versus imipenem and with Klebsiella pneumoniae versus ofloxacin

75 susceptibility (piperacillin-tazobactam and imipenem) and others toward false resistance (aztreonam,

76 active (1-Zn), product-inhibited (1-Zn plus imipenem), and inactive (2-Zn) forms.

77 oducibility among MICs was most variable for imipenem, and agreement by interpretive category was low

78 r intermediate to cefoxitin, clarithromycin, imipenem, and amikacin.

79 a selective medium incorporating vancomycin, imipenem, and amphotericin B.

80 new non-beta-lactam inhibitors (MK-7655 with imipenem, and avibactam with ceftazidime and ceftaroline

81 ducing strains were susceptible to cefepime, imipenem, and ertapenem but that with a high inoculum, m

82 amase enzyme and the carbapenems, meropenem, imipenem, and ertapenem, have been studied by Raman micr

83 sistance to third-generation cephalosporins, imipenem, and fluoroquinolones in Escherichia coli, Kleb

84 by resistance to piperacillin, ceftazidime, imipenem, and FQ.

85 d, tigecycline, and vancomycin; minocycline, imipenem, and meropenem were also highly active (>92% su

86 ation method and a MIC screen for ertapenem, imipenem, and meropenem.

87 a-lactams, aztreonam, cefepime, ceftazidime, imipenem, and piperacillin-tazobactam, were tested.

88 as resistant to ceftazidime, azlocillin, and imipenem, and sensitive to tobramycin and ciprofloxacin.

89 ible or intermediate to amikacin, cefoxitin, imipenem, and the fluoroquinolones and sulfonamides but

90 ciprofloxacin, clarithromycin, doxycycline, imipenem, and trimethoprim-sulfamethoxazole in each of f

91 vitro activities of penicillin, ampicillin, imipenem, and vancomycin against 201 blood isolates of E

92 treatment with a combination of ampicillin, imipenem, and vancomycin was compared with that of two-d

93 r ceftazidime; 71 and 19%, respectively, for imipenem; and 50 and 50%, respectively, for piperacillin

94 safety of the combination of fosfomycin and imipenem as rescue therapy for MRSA infective endocardit

95 1000 mg every 8 hrs 4-hr infusion, 92%, 97%; imipenem at 1000 mg every 8 h 3-h infusion, 77%, 83%; me

96 500 mg every 8 hrs 1-hr infusion, 73%, 79%; imipenem at 500 mg every 6 hrs 0.5-hr infusion, 62%, 69%

97 75 to 82% of the strains were susceptible to imipenem at an MIC of < or = 4 micrograms/ml.

98 covalent conjugates with benzyl penicillin, imipenem, aztreonam, and the siderophore-conjugated mono

99 d similarly with metronidazole or vancomycin-imipenem before or after receiving 5% dextran sodium sul

100 y ID consultation and PPRF for meropenem and imipenem beyond 72 hours resulted in a significant and s

101 As a result, the protein architecture and imipenem binding mode remain unchanged.

102 6 containing meropenem and GNS-F7 containing imipenem) (bioMerieux Vitek, Inc., Durham, N.C.).

103 sm is susceptible to the aminoglycosides and imipenem but resistant to the cephalosporins and ciprofl

104 iscaviarum isolates were highly resistant to imipenem, but N. cyriacigeorgica, N. asteroides, N. farc

105 ting of penicillin or ampicillin, testing of imipenem by clinical laboratories probably is not necess

106 ro susceptibility to carbapenems (meropenem, imipenem) by MIC and disk diffusion methods and to compa

107 Since the susceptibility of enterococci to imipenem can be predicted by the results obtained by tes

108 int, and trough concentrations of meropenem, imipenem, cefepime, cefazolin, levofloxacin, and piperac

109 siella pneumoniae when exposed to meropenem, imipenem, cefepime, cefazolin, levofloxacin, and piperac

110 Meropenem, imipenem, cefepime, ceftazidime (2 g every 8 hrs), and p

111 ns examined included cefoxitin-piperacillin, imipenem-cefotaxime, imipenem-ceftazidime, imipenem-pipe

112 idime, imipenem-piperacillin-tazobactam, and imipenem-cefoxitin.

113 cefoxitin-piperacillin, imipenem-cefotaxime, imipenem-ceftazidime, imipenem-piperacillin-tazobactam,

114 ll 29 positions indicates that hydrolysis of imipenem, cephaloridine and ampicillin has stringent seq

115 o specify active-site pockets that carry out imipenem, cephaloridine or ampicillin hydrolysis than on

116 sed antibiotics, including the beta-lactams, imipenems, cephalosporins, and glycopeptides.

117 antimicrobials at standard doses: meropenem, imipenem-cilastatin, ceftazidime, cefepime, piperacillin

118 rba NP test that utilized intravenous (i.v.) imipenem-cilastatin, which is less expensive than refere

119 received buprenorphine (0.05 mg/kg, SC) and imipenem/cilastatin (14 mg/kg, SC) in 1.5 mL of warm sal

120 mes, as did 219 of 270 patients treated with imipenem/cilastatin (81%).

121 All 204 subjects underwent skin tests with imipenem/cilastatin and meropenem; 130 of them were skin

122 was conducted to compare clinafloxacin with imipenem/cilastatin as adjuncts in the management of com

123 iprofloxacin/metronidazole was compared with imipenem/cilastatin for treatment of complicated intra-a

124 y found a 5.5% rate of cross-reactivity with imipenem/cilastatin in subjects with T-cell-mediated hyp

125 ment failure who were initially treated with imipenem/cilastatin.

126 Adults with HABP/VABP were randomized 1:1 to imipenem/cilastatin/relebactam 500 mg/500 mg/250 mg or p

127 s: day 28 all-cause mortality was 15.9% with imipenem/cilastatin/relebactam and 21.3% with piperacill

128 ountries), the MITT population comprised 264 imipenem/cilastatin/relebactam and 267 piperacillin/tazo

129 us adverse events (AEs) occurred in 26.7% of imipenem/cilastatin/relebactam and 32.0% of piperacillin

130 We evaluated efficacy and safety of imipenem/cilastatin/relebactam in treating hospital-acqu

131 Imipenem/cilastatin/relebactam is an appropriate treatme

132 Imipenem/cilastatin/relebactam was noninferior (P < .001

133 ding cefotetan, ticarcillin-clavulanate, and imipenem-cilastin.

134 richia coli PBP 5 as covalent complexes with imipenem, cloxacillin, and cefoxitin.

135 d puncture without antibiotics (CLP) or with imipenem (CLP + Abx).

136 antibiotics among piperacillin, ceftazidime, imipenem, colistine, and fluoroquinolones (FQ).

137 Imipenem combined with the beta-lactamase inhibitor rele

138 In addition, at high imipenem concentrations a number of residues that do not

139 ease (ID) consultation for all meropenem and imipenem courses > 72 hours.

140 y among non-Enterobacteriaceae were low, but imipenem demonstrated a sensitivity and specificity of 9

141 Imipenem demonstrated the most in vitro activity, and te

142 urveillance culture into broth containing an imipenem disk appeared to have the greatest sensitivity

143 The imipenem disk diffusion test appears compromised and sho

144 veillance specimens into broth containing an imipenem disk is an easy method for screening samples fo

145 creening medium, which involved using 10-mug imipenem disks, was investigated.

146 The crystal structure of PenA with imipenem docked into the active site suggests why this c

147 Compound 16 potentiated imipenem efficacy against resistant clinical and laborat

148 ng cell morphology changes (spheroplast with imipenem, filamentous cells with cefoxitin and ceftriaxo

149 in tryptic soy broth containing 2 microg/ml imipenem followed by plating to MacConkey agar (MAC) (me

150 MICs of imipenem for 68 unique clinical isolates of P. aeruginos

151 Mice received imipenem for antibiotic therapy, and groups were sacrifi

152 pecific than selective broth enrichment with imipenem for detection of KPC-producing K. pneumoniae an

153 the reformulated piperacillin-tazobactam and imipenem found on the AST-GN69 card, with no very major

154 owered the MIC breakpoints for meropenem and imipenem from 4 mg/liter to 1 mg/liter for Enterobacteri

155 d protect broad spectrum antibiotics such as imipenem from hydrolysis and thus extend their utility.

156 The isolates were susceptible to ampicillin, imipenem, gentamicin, amikacin, and trimethoprim-sulfame

157 ation with cefazolin, ceftriaxone, cefepime, imipenem, gentamicin, tigecycline, doxycycline, and rifa

158 susceptibility of Pseudomonas aeruginosa to imipenem has been shown to vary according to zinc concen

159 Although imipenem has in vitro activity against Enterococcus faec

160 ombinations using colistin, tigecycline, and imipenem have recently been associated with improved sur

161 sting active-site residues are optimized for imipenem hydrolysis.

162 xime, cefotetan, ceftriaxone, cefoxitin, and imipenem in addition to clindamycin but were resistant t

163 (ciprofloxacin, metronidazole, or vancomycin-imipenem) in drinking water or water alone in either pre

164 Its advantages over imipenem include greater activity against gram-negative

165 dicator of KPC resistance than meropenem and imipenem independently of the method used.

166 s (tobramycin, ciprofloxacin, aztreonam, and imipenem), indicating that this has potential clinical r

167 However, imipenem-induced bacterial killing resulted in significa

168 e was a significant decline in meropenem and imipenem initiation ("first starts") in the post-interve

169 udomonas aeruginosa that were reported to be imipenem intermediate or resistant.

170 conformation of Tyr-105 hindered docking of imipenem into the active site of PenI.

171 metronidazole intravenously (CIP/MTZ IV) or imipenem intravenously (IMI IV) throughout their treatme

172 lo-beta-lactamases based on the reduction of imipenem (IP) or ceftazidime (TZ) MICs in the presence o

173 h in combination with subefficacious dose of imipenem (IPM) robustly lowered the bacterial burden in

174 arious concentrations]) and the beta-lactams imipenem (IPM), meropenem (MEM), ertapenem (ERT), and ce

175 Imipenem (IPM), meropenem (MEM), ertapenem (ERT), and do

176 Imipenem is approved by the U.S.

177 For example, MK-7655, in combination with imipenem, is in clinical development for the treatment o

178 The reaction of 1-Zn ImiS with imipenem leads to a product-bound species, coordinated t

179 ore part of the two compounds, being that of imipenem less bulky and hydrophobic.

180 in, ciprofloxacin, gatifloxacin, gentamicin, imipenem, levofloxacin, meropenem, tobramycin, and trime

181 eptible in vitro to amikacin, ciprofloxacin, imipenem, linezolid, moxifloxacin, and trimethoprim-sulf

182 ed in culture with the carbapenem antibiotic imipenem manifests markedly altered profiles of TNF-alph

183 We next showed that the carbapenems (imipenem, meropenem, and doripenem) form long-lived acyl

184 iabetic patient was shown to be resistant to imipenem, meropenem, and ertapenem by disk diffusion sus

185 PC, NDM, and/or OXA carbapenemases, by using imipenem, meropenem, and ertapenem with LC-MS/MS assays.

186 Susceptibilities to piperacillin-tazobactam, imipenem, meropenem, and trovafloxacin remained virtuall

187 ipseudomonal agents was tested: ceftazidime, imipenem, meropenem, ceftazidime-avibactam, and imipenem

188 The imipenem, meropenem, doripenem, and ertapenem MIC50 valu

189 Minocycline, imipenem, meropenem, piperacillin, and piperacillin-tazo

190 It was resistant to imipenem (MIC, >256 mug/ml) and meropenem (MIC, 128 mug/

191 , and NDM, respectively, were susceptible to imipenem (MIC, </=1 mug/ml).

192 ited) and was 8- to 16-fold more potent than imipenem (MIC50, 1 microgram/ml; MIC90, 2 micrograms/ml)

193 with caution for detecting strains for which imipenem MICs are elevated.

194 e, ceftriaxone, ciprofloxacin, erythromycin, imipenem, minocycline, and trimethoprim-sulfamethoxazole

195 ydrolyzed ceftazidime poorly, and hydrolyzed imipenem more efficiently than ampicillin in contrast to

196 In both animal models vancomycin-imipenem most effectively prevented and treated colitis.

197 growth during exposure to colistin (n = 35), imipenem (n = 1) or ciprofloxacin (n = 1) in addition to

198 randomly received saline (n = 60), 20 mg/kg imipenem (n = 62), or 10 mg/kg ciprofloxacin (n = 60) ev

199 : Ceftazidime (n=2942), Gentamicin (n=4360), Imipenem (n=2235), Ofloxacin (n=3117) and Sulfamethoxazo

200 omplicated urinary tract infection caused by imipenem-nonsusceptible (but colistin- and imipenem/rele

201 bactam can restore imipenem activity against imipenem-nonsusceptible gram-negative pathogens.

202 e evaluated imipenem/relebactam for treating imipenem-nonsusceptible infections.

203 Staphylococcus aureus killed during imipenem or ceftazidime chemotherapy in mice elicited an

204 t observed without the antibiotic treatment (imipenem or ceftazidime).

205 a coli resistance to ampicillin, cefotaxime, imipenem or cephaloridine.

206 linically relevant antimicrobials (colistin, imipenem or ciprofloxacin) by Transposon Directed Insert

207 50.0%) followed by ciprofloxacin (32.6%) and imipenem or meropenem (28.7%).

208 osocomial infection empirically treated with imipenem or meropenem (OR, 0.35 [95% CI, .14-.87]).

209 The sensitivity of KPC or NDM to predict imipenem or meropenem resistance was 94.3% overall, and

210 cycline and ciprofloxacin paired with either imipenem or meropenem were the most active combinations

211 resistant to carbapenem antibiotics (either imipenem or meropenem).

212 s suggest that empirical therapy with either imipenem or metronidazole should be considered.

213 teriaceae infections treated with meropenem, imipenem, or doripenem.

214 distributions differed by unit type only for imipenem (p < .01).

215 icin (P<0.0001), tobramycin (P = 0.005), and imipenem (P<0.0001).

216 in 71% imipenem/relebactam and 70% colistin+imipenem patients (90% confidence interval [CI] for diff

217 % of imipenem/relebactam and 31% of colistin+imipenem patients, drug-related AEs in 16% and 31% (no d

218 acylation rate constants for the antibiotics imipenem, penicillin G, and ceftriaxone.

219 pped from 2,000-fold to 70-fold with 4 mg of imipenem per kg given at the time of challenge.

220 , imipenem-cefotaxime, imipenem-ceftazidime, imipenem-piperacillin-tazobactam, and imipenem-cefoxitin

221 Of all of the combinations, imipenem/piperacillin-tazobactam provided the greatest s

222 ype beta-lactamase family, GES-1, turns over imipenem poorly, but the GES-5 beta-lactamase is an avid

223 ch is less expensive than reference standard imipenem powder, and an updated version of the Rosco Neo

224 eriaceae, nonsusceptibility to ertapenem and imipenem predicted the presence of bla(KPC) poorly, espe

225 LP) alone and in combination with antibiotic imipenem protected both young adult (10-12 week old) and

226 Meropenem and imipenem provided high probabilities of achieving their

227 penem, meropenem, ceftazidime-avibactam, and imipenem-relebactam (an investigational beta-lactam/beta

228 % of the isolates tested were susceptible to imipenem-relebactam by BMD.

229 the therapeutic potential of the amoxicillin-imipenem-relebactam combination.

230 ts to those of broth microdilution (BMD) for imipenem-relebactam susceptibility testing using a colle

231 me-avibactam, 92.8%, 2 mug/ml, and 8 mug/ml; imipenem-relebactam, 91.5%, 0.25 mug/ml, and 2 mug/ml; c

232 Etest yielded comparable results to BMD for imipenem-relebactam.

233 ere susceptible to ceftazidime-avibactam and imipenem-relebactam.

234 Thirty-one patients received imipenem/relebactam and 16 colistin+imipenem.

235 ious adverse events (AEs) occurred in 10% of imipenem/relebactam and 31% of colistin+imipenem patient

236 vorable overall response was observed in 71% imipenem/relebactam and 70% colistin+imipenem patients (

237 We evaluated imipenem/relebactam for treating imipenem-nonsusceptible

238 Imipenem/relebactam is an efficacious and well-tolerated

239 ) pathogens were randomized 2:1 to 5-21 days imipenem/relebactam or colistin+imipenem.

240 Among mITT patients (n = 21 imipenem/relebactam, n = 10 colistin+imipenem), 29% had

241 y imipenem-nonsusceptible (but colistin- and imipenem/relebactam-susceptible) pathogens were randomiz

242 lysis of carbapenemases by PCR revealed that imipenem resistance but not meropenem resistance was ass

243 This occurred at the price of increased imipenem resistance in P aeruginosa, which remained susc

244 Imipenem resistance was detected in 65% of A. jandaei st

245 To investigate this overdetection of imipenem resistance, we tested 204 selected isolates fro

246 4-bp insertion in the oprD gene resulted in imipenem resistance.

247 responsible for the initial overdetection of imipenem resistance.

248 Do they include (1) Proteeae with inherent imipenem resistance; (2) porin-deficient Enterobacterale

249 prevalence of ceftazidime-resistance and 5% imipenem-resistance, RMD platforms predicted susceptibil

250 (Tn2006) was found in most (66.7%, 40 of 68) imipenem-resistant A. baumannii (genospecies 2) and also

251 To reduce mortality, rapid identification of imipenem-resistant A. baumannii complex and early initia

252 Imipenem-resistant A. baumannii complex bacteremia speci

253 5 days or more increased risk of subsequent imipenem-resistant A. baumannii complex bacteremia.

254 microbial therapy, which was correlated with imipenem-resistant A. baumannii complex but not with any

255 n criteria, including 73 (24.5%) infected by imipenem-resistant A. baumannii complex.

256 istant isolates of Enterobacteriaceae and 43 imipenem-resistant and 21 meropenem-resistant isolates o

257 Seven imipenem-resistant and five meropenem-resistant isolates

258 from the Project ICARE collection plus five imipenem-resistant challenge strains at the Centers for

259 and also spread beyond species border to all imipenem-resistant genospecies 3 (2), 13TU (2), and 10 (

260 Imipenem-resistant Pseudomonas aeruginosa (IRPA) is an e

261 Seven imipenem-resistant Pseudomonas aeruginosa isolates were

262 ncomitant 68.7% increase in the incidence of imipenem-resistant Pseudomonas aeruginosa occurred throu

263 were susceptible to amikacin, ciprofloxacin, imipenem, rifampin, trimethoprim-sulfamethoxazole (TMP-S

264 Oxa-23 demonstrates changes in meropenem or imipenem sensitivity in strain AB5075.

265 romogenic substrates (CENTA, nitrocefin, and imipenem), showing improved sensitivity and kinetic para

266 ia coli and pretreatment with vancomycin and imipenem significantly modulated the susceptibility to t

267 t, which does not require the preparation of imipenem solution and has a shelf life of 2 years.

268 as it requires frequent preparation of fresh imipenem solution.

269 the N170A enzyme in complex with hydrolyzed imipenem suggests Asn170 may prevent the inactivation of

270 f the substrates ampicillin, ceftazidime and imipenem suggests that the substrate is able to bind to

271 ciprofloxacin, clarithromycin, doxycycline, imipenem, sulfamethoxazole, and tobramycin (M. chelonae

272 aphylococcus aureus, 20% that reported <100% imipenem susceptibility for Escherichia coli, and 37% th

273 nd levofloxacin and tigecycline (both >96%); imipenem susceptibility was low (32%) in Africa while mi

274 These isolates became imipenem susceptible when the chromosomal oprD lesion wa

275 a previous surveillance culture that grew an imipenem-susceptible P. aeruginosa (ISPA) and a subseque

276 Five non-imipenem-susceptible strains were identified (MIC, 8 mic

277 (CA) for penicillin-imipenem and ampicillin-imipenem tested with E. faecalis and E. faecium by BMD w

278 Using the DD method, CA for ampicillin-imipenem tested with E. faecalis and E. faecium was >/=9

279 ed two- to threefold lower concentrations of imipenem than expected and resulted in artifactual two-

280 At high concentrations of imipenem that select for phenotypically wild-type mutant

281 In contrast, imipenem treatment of E. coli-cocultured macrophages doe

282 Meropenem and imipenem use remained steady until the intervention, whe

283 CLS guidelines for susceptibility testing of imipenem versus enterococci.

284 ate for broth microdilution (BMD) testing of imipenem versus Enterococcus species, 633 strains of E.

285 92% for other enterococci; CA for penicillin-imipenem was 91% for E. faecalis, 98% for E. faecium, an

286 Fosfomycin plus imipenem was an effective and safe combination when used

287 The combination of ampicillin with imipenem was highly active (an additional 5 log10 reduct

288 Recovery in bottles with meropenem and imipenem was more frequently observed in BacT/Alert FN P

289 itivities (95% confidence interval [CI]) for imipenem were 82% (74%, 89%) and 92% (85%, 97%) for PCR/

290 Resistance sensitivities (95% CI) for imipenem were 95% (88%, 98%) and 88% (80%, 94%) for PCR/

291 All widely-used antibiotics except imipenem were associated with an increased daily acquisi

292 Isolates that tested as susceptible to imipenem were not uncommon among carbapenemase-positive

293 of Pseudomonas aeruginosa with resistance to imipenem were traced to a defective lot of microdilution

294 f the carbapenems, the most useful agent was imipenem, where a zone diameter of </= 23 mm as a predic

295 Imipenem, which has a greater affinity for penicillin-bi

296 rategies were used for the administration of imipenem, which has broad-spectrum coverage of enteric b

297 Of these, imipenem, which has demonstrable anti-tubercular activit

298 mpound strongly affected by MexB contrary to imipenem, which is apparently poorly transported by the

299 es-apparently related to in vivo exposure to imipenem, which was also used during a period of chemoth

300 r affinity to the distal binding pocket than imipenem while both compounds are weakly bound to the pr